RVLV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RVLV is not a good buy right now for an impatient investor. The stock is technically weak (bearish MACD, trading below the pivot) and lacks Intellectia buy signals, so odds favor more chop/down before a cleaner entry. I would switch to a buy only if RVLV reclaims ~29.24 (pivot) and holds it, or if it flushes toward ~27.17 and shows a clear bounce.
Trend/price location: RVLV at 27.68 is below the pivot (29.238) and sitting near support (S1 27.957 already lost; next S2 27.166). Momentum: MACD histogram is -0.462 and negatively expanding, which signals downside momentum is strengthening (bearish). RSI: RSI_6 at ~27.38 is effectively oversold, which can produce short bounces, but oversold readings can persist in a downtrend. Moving averages: converging MAs suggest consolidation, but with MACD deteriorating, the consolidation is currently resolving bearishly. Key levels: Support 27.96 then 27.17; resistance 29.24 then 30.52 and 31.31. Pattern-based projection: Similar-pattern analysis implies ~3.5% upside over the next week and ~23.6% over the next month, but near-term (next day) is roughly flat-to-slightly negative.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
Earnings catalyst: Q4 & FY2025 results scheduled after close on 2026-02-24/25 with conference call—could re-rate the stock if revenue acceleration or margins surprise.
Fundamentals improving: Prior quarter showed strong profitability expansion (margin and earnings growth).
Analyst tone improving: Multiple firms raised price targets into 2026, implying improving confidence in profitability and tariff mitigation.
Options skew bullish (call-heavy OI/volume), suggesting traders are leaning toward upside scenarios.
Technical momentum is bearish: MACD negative and expanding, price below pivot and below S1 support—risk of a move toward S2 (~27.
or lower.
Growth debate: Recent commentary highlights that revenue growth has been slowing and the path back to double-digit growth may be a later-2026 story, limiting near-term multiple expansion.
Event risk concentration: With earnings ahead, the stock may stay rangebound or drift lower if buyers wait for confirmation.
Latest reported quarter: 2025/Q3. Revenue rose to $295.6M (+4.41% YoY), while profitability surged: net income $21.18M (+93.05% YoY) and EPS $0.29 (+93.33% YoY). Gross margin improved to 54.63% (+6.78% YoY). Summary: modest top-line growth but very strong margin/profitability expansion—bullish quality of earnings, though the market still wants clearer revenue re-acceleration.
Recent trend: Price targets have been raised across multiple firms (KeyBanc to $35 Overweight; UBS to $31 Neutral; Stifel to $33 Buy; Baird to $29 Neutral; MS to $26 Equal Weight; Roth to $30 Buy; Barclays to $24 Equal Weight; Evercore to $21 In Line). Wall Street pros: improving confidence in tariff mitigation, sustained margin strength/profitability improvements, and potential setup into 2026. Wall Street cons: several firms remain Neutral/Equal Weight due to concerns about slow/uneven revenue growth and the need to prove a sustainable sales acceleration to justify higher valuation.
